Healthcare Industry News: Eli Lilly
News Release - January 11, 2016
Industry Veteran Sherry Korczynski Joins Eagle Pharmaceuticals as Senior Vice President of MarketingWOODCLIFF LAKE, N.J.--(Healthcare Sales & Marketing Network)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) announced today that Sherry Korczynski, a pharmaceutical industry veteran with more than 20 years of experience, will join Eagle as Senior Vice President of Marketing effective immediately.
“We are very pleased to welcome Sherry to our senior management team. She is a dedicated and accomplished leader in the pharmaceutical industry whose award-winning strategies have driven exceptional revenue growth for well-known brands such as EpiPen® among others,” said Scott Tarriff, President and Chief Executive Officer. “Her depth of marketing expertise will be instrumental in driving commercial penetration of Eagle’s expanded product portfolio in 2016, including a potential new indication for Ryanodex® for the treatment of exertional heat stroke (“EHS”), if approved by the U.S. Food and Drug Administration (“FDA”). We look forward to drawing upon her long track record of success building brands to deliver results for patients, healthcare providers and shareholders,” added Tarriff.
Sherry Korczynski is an accomplished leader with more than 20 years of progressive experience in the pharmaceutical industry. Ms. Korczynski joins Eagle from Mylan Specialty, where she was Vice President of EpiPen® Marketing, driving multi-year double-digit growth in the brand’s sales and revenue. Prior to Mylan, Sherry spent 15 years at Eli Lilly and Company in multiple leadership roles within the sales organization, driving rapid growth in branded products. She is a dynamic leader known for surpassing financial objectives, expertly addressing market challenges, and building empowered, high-performing teams. Sherry received her M.B.A. from West Virginia University and her B.S. in Marketing from Penn State University.
“I am thrilled to join Eagle at this important time of growth and expansion. I look forward to marketing Eagle’s robust portfolio of products targeting unmet patient needs in multiple therapeutic areas, including oncology and emergency medicine. I am also very excited about Eagle’s pipeline of new drug products and its further development program for potential new indications of currently approved drugs, including exploring an additional indication for Eagle’s formulation of dantrolene sodium as a potential treatment for EHS. This is an exciting period for the Company and I am eager to apply my significant experience with life-saving rescue treatments to help the team deliver innovative and improved solutions to patients in need,” said Ms. Korczynski.
EpiPen® is a registered trademark of Mylan Inc. licensed exclusively to its wholly-owned subsidiary, Mylan Specialty L.P.
About Exertional Heat Stroke
Exertional heat stroke is a sudden and unpredictable life-threatening condition and constitutes one of the leading cause of death and severe injury in high school and college athletes. There is currently no approved drug therapy for EHS.
Ryanodex® is a registered trademark of Eagle Pharmaceuticals.
RYANODEX (dantrolene sodium) for injectable suspension is indicated for the treatment of malignant hyperthermia (“MH”) in conjunction with appropriate supportive measures, and for the prevention of malignant hyperthermia in patients at high risk.
Important Safety Information
RYANODEX is not a substitute for appropriate supportive measures in the treatment of malignant hyperthermia, including:
- Discontinuing triggering anesthetic agents
- Increasing oxygen
- Managing the metabolic acidosis
- Instituting cooling when necessary
- Administering diuretics to prevent late kidney injury due to myoglobinuria (the amount of mannitol in RYANODEX is insufficient to maintain diuresis).
The administration of dantrolene sodium is associated with loss of grip strength and weakness in the legs, as well as drowsiness, dizziness, dysphagia, dyspnea, and decreased inspiratory capacity. Patients should not be permitted to ambulate without assistance until they have normal strength and balance. Care must be taken to prevent extravasation of RYANODEX into the surrounding tissue due to the high pH of the reconstituted RYANODEX suspension and potential for tissue necrosis.
In February 2015, RYANODEX was granted seven years of U.S. market exclusivity for the treatment of MH by the U.S. Food and Drug Administration (“FDA”).
Ryanodex full Prescribing Information can be found at www.RYANODEX.com
About Eagle Pharmaceuticals, Inc.
Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com.
This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended and other securities laws. Forward-looking statements are statements that are not historical facts. Words such as “will,” “may,” “intends,” “anticipate(s),” “plan,” “enables,” “potentially,” “entitles,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: the effectiveness and/or success of Ms. Korczynski’s efforts on our behalf; the possibility or likelihood of the approval by the FDA of new indications for Ryanodex, including for EHS; the success of the marketing efforts around Ryanodex for EHS and Eagle’s other marketed products; whether Ryanodex becomes a potential treatment for EHS; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to manufacturing facilities, products and/or businesses; and other factors that are discussed in Eagle’s Annual Report on Form 10-K for the year ended September 30, 2014, and its other filings with the U.S. Securities and Exchange Commission. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond Eagle’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks include, but are not limited to the effectiveness of Ms. Korczynski, the possibility that the FDA may not approve Ryanodex for EHS; if Ryanodex for EHS is approved, that the market is not receptive of the product; and the other risks described in Eagle’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.
Source: Eagle Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.